Amyloid Beta-peptide (25-35) (human) Mechanistic Insights, C

Amyloid Beta-peptide (25-35) (human): Mechanistic Insights, Clinical Value, and Research Applications in Neurodegenerative Disease Models

Introduction
Amyloid Beta-peptide (25-35) (human), a synthetic fragment derived from the C-terminal region of the full-length amyloid beta (Aβ) peptide, has emerged as a pivotal research tool in the study of neurodegenerative disorders, particularly Alzheimer’s disease (AD). The peptide, comprising amino acids 25 to 35 (GSNKGAIIGLM), is recognized for its ability to recapitulate key pathological features of Aβ aggregation and neurotoxicity in vitro and in vivo (Yankner et al., 1990, Science). Unlike the full-length Aβ1-40 or Aβ1-42 peptides, Aβ25-35 is the shortest fragment that retains the neurotoxic properties of the parent molecule, making it an attractive and practical model for experimental studies (Pike et al., 1995, J Neurochem). Mechanistically, Aβ25-35 exerts its effects through the induction of oxidative stress, mitochondrial dysfunction, and the promotion of apoptotic pathways in neuronal cells. Its propensity to aggregate and form β-sheet-rich fibrils mirrors the amyloidogenic process observed in AD brains (Stefani & Dobson, 2003, J Mol Med). This peptide is widely utilized in preclinical research to elucidate the molecular underpinnings of amyloid toxicity, screen neuroprotective compounds, and model cognitive deficits associated with AD.

[Related: Poly(I:C)] Clinical Value and Applications
While Amyloid Beta-peptide (25-35) (human) is not intended for direct clinical use, its value lies in its robust application as a research reagent for modeling AD pathology. The peptide’s ability to induce neurodegeneration, synaptic dysfunction, and memory impairment in animal models has made it indispensable for preclinical drug discovery and mechanistic studies (Maurice et al., 1996, Eur J Pharmacol). Key clinical research applications include:
- **Neurotoxicity Assays:** Aβ25-35 is used to induce neuronal cell death in vitro, providing a platform for screening neuroprotective agents and elucidating cell death pathways (Furukawa et al., 1996, Neurosci Lett).
- **Animal Models of Cognitive Impairment:** Intracerebral or intracerebroventricular administration of Aβ25-35 in rodents reliably induces memory deficits and synaptic alterations, serving as a surrogate model for AD-related cognitive decline (Maurice et al., 1996, Eur J Pharmacol).
- **Oxidative Stress and Mitochondrial Dysfunction Studies:** The peptide is instrumental in dissecting the role of oxidative damage and mitochondrial impairment in neurodegeneration (Butterfield et al., 2002, J Neurochem).
- **Drug Screening:** Aβ25-35 models are employed to evaluate the efficacy of candidate compounds targeting amyloid aggregation, oxidative stress, or neuroinflammation.

[Related: Y-27632 dihydrochloride] Key Challenges and Pain Points Addressed
The study of Alzheimer’s disease and related neurodegenerative disorders is hampered by the complexity of amyloid aggregation, the heterogeneity of Aβ species, and the limitations of existing animal models. Full-length Aβ peptides (Aβ1-40, Aβ1-42) are prone to variable aggregation kinetics and batch-to-batch inconsistency, complicating experimental reproducibility (Walsh et al., 1997, J Biol Chem). Amyloid Beta-peptide (25-35) (human) addresses several key challenges:
- **Reproducibility:** Its short length and well-defined sequence facilitate consistent synthesis and aggregation, improving experimental reproducibility.
- **Rapid Aggregation:** Aβ25-35 aggregates more rapidly than full-length peptides, enabling efficient modeling of amyloid pathology within shorter experimental timelines (Pike et al., 1995, J Neurochem).
- **Cost and Practicality:** The peptide is less expensive to synthesize and handle, making it accessible for high-throughput screening and mechanistic studies.
- **Pathological Relevance:** Despite its truncated sequence, Aβ25-35 recapitulates key neurotoxic and amyloidogenic features, providing a relevant model for early-stage drug discovery and mechanistic research.

[Related: y 27632] Literature Review
A substantial body of literature supports the utility of Amyloid Beta-peptide (25-35) (human) in neurodegenerative disease research. Key studies include: 1. **Yankner et al. (1990, Science):** This seminal study demonstrated that Aβ25-35 is neurotoxic in primary neuronal cultures, establishing its relevance as a model for amyloid-induced neurodegeneration.
2. **Pike et al. (1995, J Neurochem):** The authors compared the aggregation and neurotoxic properties of various Aβ fragments, concluding that Aβ25-35 is the shortest fragment retaining full neurotoxic potential.
3. **Maurice et al. (1996, Eur J Pharmacol):** This study showed that intracerebroventricular injection of Aβ25-35 in rats induces memory deficits and synaptic alterations, validating its use in behavioral models of AD.
4. **Furukawa et al. (1996, Neurosci Lett):** The authors reported that Aβ25-35 induces apoptosis in cultured neurons via oxidative stress mechanisms, highlighting its utility in studying cell death pathways.
5. **Butterfield et al. (2002, J Neurochem):** This review summarized evidence that Aβ25-35 promotes oxidative damage and mitochondrial dysfunction, key features of AD pathology.
6. **Stefani & Dobson (2003, J Mol Med):** The review discussed the aggregation properties of Aβ25-35 and its relevance to amyloid diseases.
7. **Walsh et al. (1997, J Biol Chem):** The study addressed the challenges of working with full-length Aβ peptides and highlighted the advantages of using shorter fragments like Aβ25-35 for reproducibility.

Experimental Data and Results
Experimental studies employing Amyloid Beta-peptide (25-35) (human) have consistently demonstrated its capacity to induce hallmark features of AD pathology in vitro and in vivo. **In Vitro Studies:**
- **Neurotoxicity:** Exposure of primary cortical or hippocampal neurons to Aβ25-35 (10–50 μM) results in significant cell death within 24–72 hours, as measured by MTT reduction, LDH release, and TUNEL assays (Yankner et al., 1990, Science; Furukawa et al., 1996, Neurosci Lett).
- **Oxidative Stress:** Aβ25-35 treatment increases reactive oxygen species (ROS) production, lipid peroxidation, and protein carbonylation in neuronal cultures (Butterfield et al., 2002, J Neurochem).
- **Mitochondrial Dysfunction:** The peptide disrupts mitochondrial membrane potential, reduces ATP production, and activates caspase-dependent apoptotic pathways (Butterfield et al., 2002, J Neurochem). **In Vivo Studies:**
- **Cognitive Impairment:** Intracerebroventricular injection of Aβ25-35 (3–9 nmol) in rodents induces spatial memory deficits, as assessed by the Morris water maze and passive avoidance tests (Maurice et al., 1996, Eur J Pharmacol).
- **Synaptic Alterations:** Aβ25-35 administration leads to decreased synaptophysin expression and impaired long-term potentiation (LTP) in hippocampal slices, mirroring synaptic dysfunction in AD (Maurice et al., 1996, Eur J Pharmacol).
- **Neuroinflammation:** Increased expression of glial fibrillary acidic protein (GFAP) and pro-inflammatory cytokines has been observed following Aβ25-35 administration, supporting its role in modeling neuroinflammatory aspects of AD (Stefani & Dobson, 2003, J Mol Med). **Drug Screening:**
- Numerous studies have utilized Aβ25-35-induced models to evaluate neuroprotective agents, including antioxidants, anti-inflammatory compounds, and amyloid aggregation inhibitors. Positive hits in these models have progressed to further validation with full-length Aβ peptides and transgenic animal models (Butterfield et al., 2002, J Neurochem).

Usage Guidelines and Best Practices
To maximize the utility and reproducibility of experiments involving Amyloid Beta-peptide (25-35) (human), adherence to standardized protocols is essential. **Preparation and Handling:**
- The peptide should be dissolved in sterile distilled water or physiological saline to a stock concentration (e.g., 1 mM).
- To induce aggregation, incubate the peptide solution at 37°C for 24–48 hours prior to use (Pike et al., 1995, J Neurochem).
- Avoid repeated freeze-thaw cycles; aliquot and store at –20°C. **In Vitro Applications:**
- Typical working concentrations range from 10–50 μM, depending on cell type and experimental design.
- Include appropriate controls (vehicle, scrambled peptide) to account for non Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 58 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11497020